CN103893129B - 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 - Google Patents
帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 Download PDFInfo
- Publication number
- CN103893129B CN103893129B CN201210585393.8A CN201210585393A CN103893129B CN 103893129 B CN103893129 B CN 103893129B CN 201210585393 A CN201210585393 A CN 201210585393A CN 103893129 B CN103893129 B CN 103893129B
- Authority
- CN
- China
- Prior art keywords
- paliperidone
- spheres
- sustained
- release micro
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 147
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 229960001057 paliperidone Drugs 0.000 title claims abstract description 89
- 238000013268 sustained release Methods 0.000 title claims abstract description 67
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 67
- 238000002347 injection Methods 0.000 title claims abstract description 15
- 239000007924 injection Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000002245 particle Substances 0.000 claims abstract description 27
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 27
- 239000000243 solution Substances 0.000 claims description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 20
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 20
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000013019 agitation Methods 0.000 claims description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 208000035126 Facies Diseases 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 60
- 229940079593 drug Drugs 0.000 abstract description 40
- 238000011068 loading method Methods 0.000 abstract description 19
- 239000008346 aqueous phase Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 239000011806 microball Substances 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011805 ball Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000000280 densification Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940032510 trelstar Drugs 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210585393.8A CN103893129B (zh) | 2012-12-28 | 2012-12-28 | 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210585393.8A CN103893129B (zh) | 2012-12-28 | 2012-12-28 | 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103893129A CN103893129A (zh) | 2014-07-02 |
CN103893129B true CN103893129B (zh) | 2016-10-05 |
Family
ID=50984925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210585393.8A Expired - Fee Related CN103893129B (zh) | 2012-12-28 | 2012-12-28 | 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103893129B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104502466B (zh) * | 2014-11-20 | 2021-01-26 | 万全万特制药(厦门)有限公司 | 一种用液相色谱法分离测定帕潘立酮原料及其制剂的方法 |
CN104940150B (zh) * | 2015-06-16 | 2020-11-20 | 黑龙江大学 | 一种帕利哌酮缓释微球注射剂的制备方法 |
CN106474070B (zh) * | 2015-08-26 | 2020-03-17 | 四川科伦药物研究院有限公司 | 一种克服停滞期、恒速释放疏水性药物的微球及制备方法 |
CN114159411A (zh) * | 2021-10-21 | 2022-03-11 | 广东省科学院健康医学研究所 | 一种载药聚合物微球及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511347A (zh) * | 2006-08-31 | 2009-08-19 | Sk化学株式会社 | 含药物微球的制造方法及由该方法制造的含药物微球 |
CN101653422A (zh) * | 2008-08-20 | 2010-02-24 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
-
2012
- 2012-12-28 CN CN201210585393.8A patent/CN103893129B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511347A (zh) * | 2006-08-31 | 2009-08-19 | Sk化学株式会社 | 含药物微球的制造方法及由该方法制造的含药物微球 |
CN101653422A (zh) * | 2008-08-20 | 2010-02-24 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
利培酮长效注射微球的制备及体外释放的研究;孔蕾;《中国药师》;20091231;第12卷(第12期);摘要,第1714页2.1利培酮微球的制备、图1,第1715页3讨论 * |
Also Published As
Publication number | Publication date |
---|---|
CN103893129A (zh) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103260603B (zh) | 用于治疗关节痛的皮质类固醇 | |
RU2586306C2 (ru) | Состав с микросферами для длительного непрерывного высвобождения рисперидона | |
Wischke et al. | Development of PLGA-based injectable delivery systems for hydrophobic fenretinide | |
CN105310997B (zh) | 一种阿立哌唑缓释微球及其制备方法 | |
CN103893129B (zh) | 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法 | |
WO2019218409A1 (zh) | 一种阿立哌唑缓释微球及其制备方法 | |
US20240016744A1 (en) | Naltrexone and risperidone combination sustained-release composition | |
CN101797232B (zh) | 一种制备注射用小粒径重组人血管内皮抑制素缓释微粒的方法 | |
CN102641281B (zh) | 一种注射用单唾液酸四己糖神经节苷脂钠及其制备方法 | |
de Souza et al. | Has PEG-PLGA advantages for the delivery of hydrophobic drugs? Risperidone as an example | |
CN114748428B (zh) | 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法 | |
US20180177777A1 (en) | Formulations for mitigating opioid overdose and methods of making and using the same | |
CN1166360C (zh) | 一种纳曲酮长效注射微球组合物及制备方法和应用 | |
CN107823145A (zh) | 一种注射用伊潘立酮plga微球及制备工艺 | |
CN103690933B (zh) | 一种干细胞因子缓释微球及其制备方法 | |
CN114681406B (zh) | 一种卡利拉嗪长效缓释微球及其制备方法 | |
CN115671057A (zh) | 一种卢美哌隆药物组合物、长效微球缓释制剂及其制备方法 | |
CN106727362A (zh) | 一种曲普瑞林微球及其制备方法与应用 | |
CN104013578B (zh) | 一种帕潘立酮衍生物缓释微球制剂及制备方法 | |
CN112121028B (zh) | 一种辛伐他汀固体纳米粒制剂及其制备方法 | |
CN100475264C (zh) | 含干扰素或其类似物的注射用缓释微球及其制备方法 | |
CN113786393A (zh) | 一种利伐沙班微球及其制备方法与应用 | |
CN108815138B (zh) | 利培酮或其衍生物缓释微球、其制备方法及用途 | |
CN105997887A (zh) | 一种含小分子添加剂的托特罗定缓释微球制剂及制备方法 | |
CN100528224C (zh) | 含干扰素α-1b的注射用缓释微球及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: CHONGQING DAXIN PHARMACEUTICAL Co.,Ltd. Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: Peking University International Hospital Group Chongqing Daxin Pharmaceutical Co.,Ltd. Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221013 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: CHONGQING DAXIN PHARMACEUTICAL Co.,Ltd. Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: CHONGQING DAXIN PHARMACEUTICAL Co.,Ltd. Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161005 |
|
CF01 | Termination of patent right due to non-payment of annual fee |